A new study has reaffirmed that Eli Lilly's (LLY) GLP-1 drugs fare better for weight loss than Novo Nordisk's (NVO). The study, conducted by researchers at hospital systems in Washington and Oregon and published by JAMA, showed that over a period of a year, patients on Novo Nordisk's diabetes drug Ozempic lost 8% of their body weight compared to 15% from Eli Lilly's diabetes drug Mounjaro. It also showed that over the course of a year, patients on Eli Lilly's drug continuously lost more weight, compared to decreased weight loss over time from Novo Nordisk's drug — 42% versus 18%, respectively, lost 15% or greater weight. The study lightly pressured Novo Nordisk's stock Tuesday, which traded down more than 2% at the bell. In a statement to Yahoo Finance, Novo claimed it wasn't a fair apples-to-apples comparison and that the study had some key deficiencies. "Novo Nordisk welcomes independent research investigating the safety and clinical utility of our products. However, the ideal way to compare two treatments is an adequately powered head-to-head randomized clinical trial (RCT) in obesity. Currently, no head-to-head trials have been completed comparing tirzepatide and semaglutide," a spokesperson said in an emailed statement. Assortment of weight loss and diabetic drugs on a table. (Douglas Cliff via Getty Images) (Douglas Cliff via Getty Images) They noted in particular that the study looked at the diabetes drugs of each company, Ozempic for Novo and Mounjaro for Lilly, which have less potent doses since their goal isn't weight loss. The weight-loss drugs for each company, Wegovy and Zepbound, respectively, include higher doses of the formula in order to achieve greater weight loss. Eli Lilly did not want to comment on the study. Instead, the company is awaiting its own head-to-head trial. "As Lilly was not involved in and did not sponsor this study, we are unable to provide comment. However, we are studying tirzepatide and semaglutide in participants with obesity in a phase 3b head-to-head trial, SURMOUNT-5, that is expected to complete later this year," a spokesperson said in an emailed statement. The study confirms the initial impression of both companies' Phase 3 data. They already showed Lilly's tirzepatide drugs do slightly better with weight loss than Novo's semaglutide — achieving as much as 21% versus 12%-14% weight loss. Lilly has already used this data in its advertising for Mounjaro, claiming Mounjaro has "unmatched weight reduction across all 3 doses vs Ozempic." An imperfect study Using patient data from Truveta, which hides identifiable information, researchers looked at an initial set of 44,000 patients and whittled it down to more than 9,000 to try and compare patients who seemed to have similar characteristics. They included obese patients, half of which were diabetic. Dr. F. Perry Wilson, the director of the clinical and translational research accelerator at Yale University, noted on X that within the initial data set, "Those who got Mounjaro were, broadly, healthier, richer, more educated, more white." But, Novo points out, the study also did not include "insurance type, socioeconomic status, baseline BMI (only baseline weight was compared and matched), frequency of interactions between patients and HCPs [health care practitioners], concomitant use of other medications with weight changing effect, among others." The researchers said in the study that they focused on patients who went for follow-up visits to health centers and those whose information was complete (including gender) — patients with missing information were not included. GLP-1s have taken the market by storm, leading to billions of additional revenue for the companies in the past year, and Wall Street expects these once-weekly injectables to contribute between $13 billion and $25 billion to Novo and Lilly's bottom lines this year. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. Follow Anjalee on all social media platforms @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices Read the latest financial and business news from Yahoo Finance
Eli Lilly awaits head-to-head study on GLP-1s after new report reaffirms superiority
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...